Pharmacogenomics is an evolving tool of precision medicine. Recently, due to the introduction of next-generation sequencing and projects generating "Big Data", a plethora of new genetic variants in pharmacogenes have been discovered. Cancer resistance is a major complication often preventing successful anticancer treatments. Pharmacogenomics of both somatic mutations in tumor cells and germline variants may help optimize targeted treatments and improve the response to conventional oncological therapy. In addition, integrative approaches combining copy number variations and long noncoding RNA profiling with germline and somatic variations seem to be a promising approach as well. In pharmacology, expression and enzyme activity are traditionally the more studied aspects of ATP-binding cassette transporters and cytochromes P450. In this review, we briefly introduce the field of pharmacogenomics and the advancements driven by next-generation sequencing and outline the possible roles of genetic variation in the two large pharmacogene superfamilies. Although the evidence needs further substantiation, somatic and copy number variants as well as rare variants and common polymorphisms in these genes could all affect response to cancer therapy. Regulation by long noncoding RNAs has also been shown to play a role. However, in all these areas, more comprehensive studies on larger sets of patients are needed.

3rd Faculty of Medicine Charles University 100 00 Prague Czech Republic

Laboratory of Pharmacogenomics Biomedical Center Faculty of Medicine in Pilsen Charles University 306 05 Pilsen Czech Republic

Toxicogenomics Unit National Institute of Public Health 100 00 Prague Czech Republic

See more in PubMed

Vogel F. Moderne Probleme der Humangenetik. Ergeb. Inn. Med. Kinderheilkd. 1959;12:52–125.

Daly A.K. Pharmacogenetics: A general review on progress to date. Br. Med. Bull. 2017;124:65–79. doi: 10.1093/bmb/ldx035. PubMed DOI

Barbarino J.M., Whirl-Carrillo M., Altman R.B., Klein T.E. PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip. Rev. Syst. Biol. Med. 2018;10:e1417. doi: 10.1002/wsbm.1417. PubMed DOI PMC

Relling M.V., Evans W.E. Pharmacogenomics in the clinic. Nature. 2015;526:343–350. doi: 10.1038/nature15817. PubMed DOI PMC

Hyman D.M., Taylor B.S., Baselga J. Implementing Genome-Driven Oncology. Cell. 2017;168:584–599. doi: 10.1016/j.cell.2016.12.015. PubMed DOI PMC

Fujikura K., Ingelman-Sundberg M., Lauschke V.M. Genetic variation in the human cytochrome P450 supergene family. Pharmacogenet. Genom. 2015;25:584–594. doi: 10.1097/FPC.0000000000000172. PubMed DOI

Kozyra M., Ingelman-Sundberg M., Lauschke V.M. Rare genetic variants in cellular transporters, metabolic enzymes, and nuclear receptors can be important determinants of interindividual differences in drug response. Genet. Med. 2017;19:20–29. doi: 10.1038/gim.2016.33. PubMed DOI

Ingelman-Sundberg M., Mkrtchian S., Zhou Y., Lauschke V.M. Integrating rare genetic variants into pharmacogenetic drug response predictions. Hum. Genom. 2018;12:26. doi: 10.1186/s40246-018-0157-3. PubMed DOI PMC

PubMed. [(accessed on 31 July 2020)]; Available online: https://pubmed.ncbi.nlm.nih.gov/

Hertz D.L., McLeod H.L. Use of pharmacogenetics for predicting cancer prognosis and treatment exposure, response and toxicity. J. Hum. Genet. 2013;58:346–352. doi: 10.1038/jhg.2013.42. PubMed DOI

McLeod H.L. Cancer pharmacogenomics: Early promise, but concerted effort needed. Science. 2013;339:1563–1566. doi: 10.1126/science.1234139. PubMed DOI PMC

Lam S.W., Frederiks C.N., van der Straaten T., Honkoop A.H., Guchelaar H.J., Boven E. Genotypes of CYP2C8 and FGD4 and their association with peripheral neuropathy or early dose reduction in paclitaxel-treated breast cancer patients. Br. J. Cancer Suppl. 2016;115:1335–1342. doi: 10.1038/bjc.2016.326. PubMed DOI PMC

Abraham J.E., Guo Q., Dorling L., Tyrer J., Ingle S., Hardy R., Vallier A.L., Hiller L., Burns R., Jones L., et al. Replication of Genetic Polymorphisms Reported to Be Associated with Taxane-Related Sensory Neuropathy in Patients with Early Breast Cancer Treated with Paclitaxel. Clin. Cancer Res. 2014;20:2466–2475. doi: 10.1158/1078-0432.CCR-13-3232. PubMed DOI

FDA. [(accessed on 4 May 2020)]; Available online: https://www.fda.gov/Drugs/ScienceResearch/ucm572698.htm.

Cascorbi I., Werk A.N. Advances and challenges in hereditary cancer pharmacogenetics. Expert Opin. Drug Metab. Toxicol. 2017;13:73–82. doi: 10.1080/17425255.2017.1233965. PubMed DOI

EMA. [(accessed on 4 May 2020)]; Available online: https://www.ema.europa.eu/

Pharmacogenomics Knowledgebase. [(accessed on 31 July 2020)]; Available online: https://www.pharmgkb.org/

Whirl-Carrillo M., McDonagh E.M., Hebert J.M., Gong L., Sangkuhl K., Thorn C.F., Altman R.B., Klein T.E. Pharmacogenomics knowledge for personalized medicine. Clin. Pharmacol. Ther. 2012;92:414–417. doi: 10.1038/clpt.2012.96. PubMed DOI PMC

Drogemoller B.I., Wright G.E.B., Shih J., Monzon J.G., Gelmon K.A., Ross C.J.D., Amstutz U., Carleton B.C. CYP2D6 as a treatment decision aid for ER-positive non-metastatic breast cancer patients: A systematic review with accompanying clinical practice guidelines. Breast Cancer Res. Treat. 2019;173:521–532. doi: 10.1007/s10549-018-5027-0. PubMed DOI

Goetz M.P., Sangkuhl K., Guchelaar H.J., Schwab M., Province M., Whirl-Carrillo M., Symmans W.F., McLeod H.L., Ratain M.J., Zembutsu H., et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy. Clin. Pharmacol. Ther. 2018;103:770–777. doi: 10.1002/cpt.1007. PubMed DOI PMC

Cronin-Fenton D.P., Damkier P., Lash T.L. Metabolism and transport of tamoxifen in relation to its effectiveness: New perspectives on an ongoing controversy. Future Oncol. 2014;10:107–122. doi: 10.2217/fon.13.168. PubMed DOI PMC

Lyon E., Gastier Foster J., Palomaki G.E., Pratt V.M., Reynolds K., Sabato M.F., Scott S.A., Vitazka P. Laboratory testing of CYP2D6 alleles in relation to tamoxifen therapy. Genet. Med. 2012;14:990–1000. doi: 10.1038/gim.2012.108. PubMed DOI

Shao X., Cai J., Zheng Y., Wang J., Feng J., Huang Y., Shi L., Chen Z., Guo Y., Wang X. S4646 polymorphism in CYP19A1 gene is associated with the efficacy of hormone therapy in early breast cancer. Int. J. Clin. Exp. Pathol. 2015;8:5309–5317. PubMed PMC

Shao X., Guo Y., Xu X., Zheng Y., Wang J., Chen Z., Huang J., Huang P., Cai J., Wang X. The CYP19 RS4646 polymorphism IS related to the prognosis of stage I-II and operable stage III breast cancer. PLoS ONE. 2015;10:e0121535. doi: 10.1371/journal.pone.0121535. PubMed DOI PMC

Scharfe C.P.I., Tremmel R., Schwab M., Kohlbacher O., Marks D.S. Genetic variation in human drug-related genes. Genome Med. 2017;9:117. doi: 10.1186/s13073-017-0502-5. PubMed DOI PMC

Xiao Q., Zhou Y., Winter S., Buttner F., Schaeffeler E., Schwab M., Lauschke V.M. Germline variant burden in multidrug resistance transporters is a therapy-specific predictor of survival in breast cancer patients. Int. J. Cancer. 2020;146:2475–2487. doi: 10.1002/ijc.32898. PubMed DOI

Menden M.P., Casale F.P., Stephan J., Bignell G.R., Iorio F., McDermott U., Garnett M.J., Saez-Rodriguez J., Stegle O. The germline genetic component of drug sensitivity in cancer cell lines. Nat. Commun. 2018;9:3385. doi: 10.1038/s41467-018-05811-3. PubMed DOI PMC

Caronia D., Patino-Garcia A., Perez-Martinez A., Pita G., Moreno L.T., Zalacain-Diez M., Molina B., Colmenero I., Sierrasesumaga L., Benitez J., et al. Effect of ABCB1 and ABCC3 polymorphisms on osteosarcoma survival after chemotherapy: A pharmacogenetic study. PLoS ONE. 2011;6:e26091. doi: 10.1371/journal.pone.0026091. PubMed DOI PMC

Kalra S., Kaur R.P., Ludhiadch A., Shafi G., Vashista R., Kumar R., Munshi A. Association of CYP2C19*2 and ALDH1A1*1/*2 variants with disease outcome in breast cancer patients: Results of a global screening array. Eur. J. Clin. Pharmacol. 2018;74:1291–1298. doi: 10.1007/s00228-018-2505-6. PubMed DOI

Green H., Soderkvist P., Rosenberg P., Horvath G., Peterson C. mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy. Clin. Cancer Res. 2006;12:854–859. doi: 10.1158/1078-0432.CCR-05-0950. PubMed DOI

Chang H., Rha S.Y., Jeung H.C., Im C.K., Ahn J.B., Kwon W.S., Yoo N.C., Roh J.K., Chung H.C. Association of the ABCB1 gene polymorphisms 2677G>T/A and 3435C>T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients. Ann. Oncol. 2009;20:272–277. doi: 10.1093/annonc/mdn624. PubMed DOI

Chu Y.H., Li H., Tan H.S., Koh V., Lai J., Phyo W.M., Choudhury Y., Kanesvaran R., Chau N.M., Toh C.K., et al. Association of ABCB1 and FLT3 Polymorphisms with Toxicities and Survival in Asian Patients Receiving Sunitinib for Renal Cell Carcinoma. PLoS ONE. 2015;10:e0134102. doi: 10.1371/journal.pone.0134102. PubMed DOI PMC

Beuselinck B., Lambrechts D., Van Brussel T., Wolter P., Cardinaels N., Joniau S., Lerut E., Karadimou A., Couchy G., Sebe P., et al. Efflux pump ABCB1 single nucleotide polymorphisms and dose reductions in patients with metastatic renal cell carcinoma treated with sunitinib. Acta. Oncol. 2014;53:1413–1422. doi: 10.3109/0284186X.2014.918276. PubMed DOI

Harivenkatesh N., Kumar L., Bakhshi S., Sharma A., Kabra M., Velpandian T., Gogia A., Shastri S.S., Gupta Y.K. Do polymorphisms in MDR1 and CYP3A5 genes influence the risk of cytogenetic relapse in patients with chronic myeloid leukemia on imatinib therapy? Leuk. Lymphoma. 2017;58:1–9. doi: 10.1080/10428194.2017.1287359. PubMed DOI

Ben Hassine I., Gharbi H., Soltani I., Ben Hadj Othman H., Farrah A., Amouri H., Teber M., Ghedira H., Ben Youssef Y., Safra I., et al. Molecular study of ABCB1 gene and its correlation with imatinib response in chronic myeloid leukemia. Cancer Chemother. Pharmacol. 2017;80:829–839. doi: 10.1007/s00280-017-3424-4. PubMed DOI

Zheng Q., Wu H., Yu Q., Kim D.H., Lipton J.H., Angelini S., Soverini S., Vivona D., Takahashi N., Cao J. ABCB1 polymorphisms predict imatinib response in chronic myeloid leukemia patients: A systematic review and meta-analysis. Pharmacogenom. J. 2015;15:127–134. doi: 10.1038/tpj.2014.54. PubMed DOI

Kim D.H., Park J.Y., Sohn S.K., Lee N.Y., Baek J.H., Jeon S.B., Kim J.G., Suh J.S., Do Y.R., Lee K.B. Multidrug resistance-1 gene polymorphisms associated with treatment outcomes in de novo acute myeloid leukemia. Int. J. Cancer. 2006;118:2195–2201. doi: 10.1002/ijc.21666. PubMed DOI

Green H., Falk I.J., Lotfi K., Paul E., Hermansson M., Rosenquist R., Paul C., Nahi H. Association of ABCB1 polymorphisms with survival and in vitro cytotoxicty in de novo acute myeloid leukemia with normal karyotype. Pharmacogenom. J. 2012;12:111–118. doi: 10.1038/tpj.2010.79. PubMed DOI

Megias-Vericat J.E., Rojas L., Herrero M.J., Boso V., Montesinos P., Moscardo F., Poveda J.L., Sanz M.A., Alino S.F. Influence of ABCB1 polymorphisms upon the effectiveness of standard treatment for acute myeloid leukemia: A systematic review and meta-analysis of observational studies. Pharmacogenom. J. 2015;15:109–118. doi: 10.1038/tpj.2014.80. PubMed DOI

He H., Yin J., Li X., Zhang Y., Xu X., Zhai M., Chen J., Qian C., Zhou H., Liu Z. Association of ABCB1 polymorphisms with prognostic outcomes of anthracycline and cytarabine in Chinese patients with acute myeloid leukemia. Eur. J. Clin. Pharmacol. 2015;71:293–302. doi: 10.1007/s00228-014-1795-6. PubMed DOI

Yin J.Y., Huang Q., Zhao Y.C., Zhou H.H., Liu Z.Q. Meta-analysis on pharmacogenetics of platinum-based chemotherapy in non small cell lung cancer (NSCLC) patients. PLoS ONE. 2012;7:e38150. doi: 10.1371/journal.pone.0038150. PubMed DOI PMC

Jakobsen Falk I., Lund J., Green H., Gruber A., Alici E., Lauri B., Blimark C., Mellqvist U.H., Swedin A., Forsberg K., et al. Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma: Results from a phase IV observational study and subsequent phase II clinical trial. Cancer Chemother. Pharmacol. 2018;81:183–193. doi: 10.1007/s00280-017-3481-8. PubMed DOI PMC

Bray J., Sludden J., Griffin M.J., Cole M., Verrill M., Jamieson D., Boddy A.V. Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide. Br. J. Cancer. 2010;102:1003–1009. doi: 10.1038/sj.bjc.6605587. PubMed DOI PMC

Lal S., Wong Z.W., Sandanaraj E., Xiang X., Ang P.C., Lee E.J., Chowbay B. Influence of ABCB1 and ABCG2 polymorphisms on doxorubicin disposition in Asian breast cancer patients. Cancer Sci. 2008;99:816–823. doi: 10.1111/j.1349-7006.2008.00744.x. PubMed DOI PMC

Maggini V., Buda G., Martino A., Presciuttini S., Galimberti S., Orciuolo E., Barale R., Petrini M., Rossi A.M. MDR1 diplotypes as prognostic markers in multiple myeloma. Pharm. Genom. 2008;18:383–389. doi: 10.1097/FPC.0b013e3282f82297. PubMed DOI

Wu H., Kang H., Liu Y., Xiao Q., Zhang Y., Sun M., Liu D., Wang Z., Zhao H., Yao W., et al. Association of ABCB1 genetic polymorphisms with susceptibility to colorectal cancer and therapeutic prognosis. Pharmacogenomics. 2013;14:897–911. doi: 10.2217/pgs.13.78. PubMed DOI

Grau J.J., Caballero M., Campayo M., Jansa S., Vargas M., Alos L., Monzo M. Gene single nucleotide polymorphism accumulation improves survival in advanced head and neck cancer patients treated with weekly paclitaxel. Laryngoscope. 2009;119:1484–1490. doi: 10.1002/lary.20254. PubMed DOI

Hertz D.L., Motsinger-Reif A.A., Drobish A., Winham S.J., McLeod H.L., Carey L.A., Dees E.C. CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel. Breast Cancer Res. Treat. 2012;134:401–410. doi: 10.1007/s10549-012-2054-0. PubMed DOI PMC

Angelini S., Soverini S., Ravegnini G., Barnett M., Turrini E., Thornquist M., Pane F., Hughes T.P., White D.L., Radich J., et al. Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy. Haematologica. 2013;98:193–200. doi: 10.3324/haematol.2012.066480. PubMed DOI PMC

Adeagbo B.A., Bolaji O.O., Olugbade T.A., Durosinmi M.A., Bolarinwa R.A., Masimirembwa C. Influence of CYP3A5*3 and ABCB1 C3435T on clinical outcomes and trough plasma concentrations of imatinib in Nigerians with chronic myeloid leukaemia. J. Clin. Pharm. Ther. 2016;41:546–551. doi: 10.1111/jcpt.12424. PubMed DOI

Kafka A., Sauer G., Jaeger C., Grundmann R., Kreienberg R., Zeillinger R., Deissler H. Polymorphism C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancer. Int. J. Oncol. 2003;22:1117–1121. doi: 10.3892/ijo.22.5.1117. PubMed DOI

Narumiya K., Metzger R., Bollschweiler E., Alakus H., Brabender J., Drebber U., Holscher A.H., Warnecke-Eberz U. Impact of ABCB1 C3435T polymorphism on lymph node regression in multimodality treatment of locally advanced esophageal cancer. Pharmacogenomics. 2011;12:205–214. doi: 10.2217/pgs.10.174. PubMed DOI

McLeod H.L., Sargent D.J., Marsh S., Green E.M., King C.R., Fuchs C.S., Ramanathan R.K., Williamson S.K., Findlay B.P., Thibodeau S.N., et al. Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: Results from North American Gastrointestinal Intergroup Trial N9741. J. Clin. Oncol. 2010;28:3227–3233. doi: 10.1200/JCO.2009.21.7943. PubMed DOI PMC

Sensorn I., Sirachainan E., Chamnanphon M., Pasomsub E., Trachu N., Supavilai P., Sukasem C., Pinthong D. Association of CYP3A4/5, ABCB1 and ABCC2 polymorphisms and clinical outcomes of Thai breast cancer patients treated with tamoxifen. Pharmgenom. Pers. Med. 2013;6:93–98. doi: 10.2147/PGPM.S44006. PubMed DOI PMC

Ravegnini G., Urbini M., Simeon V., Genovese C., Astolfi A., Nannini M., Gatto L., Saponara M., Ianni M., Indio V., et al. An exploratory study by DMET array identifies a germline signature associated with imatinib response in gastrointestinal stromal tumor. Pharmacogenom. J. 2019;19:390–400. doi: 10.1038/s41397-018-0050-4. PubMed DOI

Li M., Seiser E.L., Baldwin R.M., Ramirez J., Ratain M.J., Innocenti F., Kroetz D.L. ABC transporter polymorphisms are associated with irinotecan pharmacokinetics and neutropenia. Pharmacogenom. J. 2018;18:35–42. doi: 10.1038/tpj.2016.75. PubMed DOI PMC

Kiyotani K., Mushiroda T., Imamura C.K., Hosono N., Tsunoda T., Kubo M., Tanigawara Y., Flockhart D.A., Desta Z., Skaar T.C., et al. Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J. Clin. Oncol. 2010;28:1287–1293. doi: 10.1200/JCO.2009.25.7246. PubMed DOI PMC

Ansari M., Sauty G., Labuda M., Gagne V., Rousseau J., Moghrabi A., Laverdiere C., Sinnett D., Krajinovic M. Polymorphism in multidrug resistance-associated protein gene 3 is associated with outcomes in childhood acute lymphoblastic leukemia. Pharmacogenom. J. 2012;12:386–394. doi: 10.1038/tpj.2011.17. PubMed DOI

Angelini S., Pantaleo M.A., Ravegnini G., Zenesini C., Cavrini G., Nannini M., Fumagalli E., Palassini E., Saponara M., Di Battista M., et al. Polymorphisms in OCTN1 and OCTN2 transporters genes are associated with prolonged time to progression in unresectable gastrointestinal stromal tumours treated with imatinib therapy. Pharmacol. Res. 2013;68:1–6. doi: 10.1016/j.phrs.2012.10.015. PubMed DOI

Han J.Y., Lee Y.S., Shin E.S., Hwang J.A., Nam S., Hong S.H., Ghang H.Y., Kim J.Y., Yoon S.J., Lee J.S. A genome-wide association study of survival in small-cell lung cancer patients treated with irinotecan plus cisplatin chemotherapy. Pharmacogenom. J. 2014;14:20–27. doi: 10.1038/tpj.2013.7. PubMed DOI

Zhao J., Li W., Zhu D., Yu Q., Zhang Z., Sun M., Cai S., Zhang W. Association of single nucleotide polymorphisms in MTHFR and ABCG2 with the different efficacy of first-line chemotherapy in metastatic colorectal cancer. Med. Oncol. 2014;31:802. doi: 10.1007/s12032-013-0802-6. PubMed DOI PMC

Delord M., Rousselot P., Cayuela J.M., Sigaux F., Guilhot J., Preudhomme C., Guilhot F., Loiseau P., Raffoux E., Geromin D., et al. High imatinib dose overcomes insufficient response associated with ABCG2 haplotype in chronic myelogenous leukemia patients. Oncotarget. 2013;4:1582–1591. doi: 10.18632/oncotarget.1050. PubMed DOI PMC

De Mattia E., Toffoli G., Polesel J., D’Andrea M., Corona G., Zagonel V., Buonadonna A., Dreussi E., Cecchin E. Pharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatment. Pharmacogenet. Genom. 2013;23:549–557. doi: 10.1097/FPC.0b013e328364b6cf. PubMed DOI

Limviphuvadh V., Tan C.S., Konishi F., Jenjaroenpun P., Xiang J.S., Kremenska Y., Mu Y.S., Syn N., Lee S.C., Soo R.A., et al. Discovering novel SNPs that are correlated with patient outcome in a Singaporean cancer patient cohort treated with gemcitabine-based chemotherapy. BMC Cancer. 2018;18:555. doi: 10.1186/s12885-018-4471-x. PubMed DOI PMC

Dong N., Yu J., Wang C., Zheng X., Wang Z., Di L., Song G., Zhu B., Che L., Jia J., et al. Pharmacogenetic assessment of clinical outcome in patients with metastatic breast cancer treated with docetaxel plus capecitabine. J. Cancer Res. Clin. Oncol. 2012;138:1197–1203. doi: 10.1007/s00432-012-1183-5. PubMed DOI PMC

Verboom M.C., Kloth J.S.L., Swen J.J., Sleijfer S., Reyners A.K.L., Steeghs N., Mathijssen R.H.J., Gelderblom H., Guchelaar H.J. Genetic polymorphisms in ABCG2 and CYP1A2 are associated with imatinib dose reduction in patients treated for gastrointestinal stromal tumors. Pharmacogenom. J. 2019;19:473–479. doi: 10.1038/s41397-019-0079-z. PubMed DOI

Le Morvan V., Litiere S., Laroche-Clary A., Ait-Ouferoukh S., Bellott R., Messina C., Cameron D., Bonnefoi H., Robert J. Identification of SNPs associated with response of breast cancer patients to neoadjuvant chemotherapy in the EORTC-10994 randomized phase III trial. Pharmacogenom. J. 2015;15:63–68. doi: 10.1038/tpj.2014.24. PubMed DOI

Wang H., Bian T., Liu D., Jin T., Chen Y., Lin A., Chen C. Association analysis of CYP2A6 genotypes and haplotypes with 5-fluorouracil formation from tegafur in human liver microsomes. Pharmacogenomics. 2011;12:481–492. doi: 10.2217/pgs.10.202. PubMed DOI

Kassogue Y., Quachouh M., Dehbi H., Quessar A., Benchekroun S., Nadifi S. Functional polymorphism of CYP2B6 G15631T is associated with hematologic and cytogenetic response in chronic myeloid leukemia patients treated with imatinib. Med. Oncol. 2014;31:782. doi: 10.1007/s12032-013-0782-6. PubMed DOI

Johnson G.G., Lin K., Cox T.F., Oates M., Sibson D.R., Eccles R., Lloyd B., Gardiner L.J., Carr D.F., Pirmohamed M., et al. CYP2B6*6 is an independent determinant of inferior response to fludarabine plus cyclophosphamide in chronic lymphocytic leukemia. Blood. 2013;122:4253–4258. doi: 10.1182/blood-2013-07-516666. PubMed DOI

Damkier P., Kjaersgaard A., Barker K.A., Cronin-Fenton D., Crawford A., Hellberg Y., Janssen E.A.M., Langefeld C., Ahern T.P., Lash T.L. CYP2C19*2 and CYP2C19*17 variants and effect of tamoxifen on breast cancer recurrence: Analysis of the International Tamoxifen Pharmacogenomics Consortium dataset. Sci. Rep. 2017;7:7727. doi: 10.1038/s41598-017-08091-x. PubMed DOI PMC

Suzumura T., Kimura T., Kudoh S., Umekawa K., Nagata M., Matsuura K., Tanaka H., Mitsuoka S., Yoshimura N., Kira Y., et al. Reduced CYP2D6 function is associated with gefitinib-induced rash in patients with non-small cell lung cancer. BMC Cancer. 2012;12:568. doi: 10.1186/1471-2407-12-568. PubMed DOI PMC

Sugiyama E., Umemura S., Nomura S., Kirita K., Matsumoto S., Yoh K., Niho S., Ohmatsu H., Tsuboi M., Ohe Y., et al. Impact of single nucleotide polymorphisms on severe hepatotoxicity induced by EGFR tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring EGFR mutations. Lung Cancer. 2015;90:307–313. doi: 10.1016/j.lungcan.2015.08.004. PubMed DOI

Takimoto T., Kijima T., Otani Y., Nonen S., Namba Y., Mori M., Yokota S., Minami S., Komuta K., Uchida J., et al. Polymorphisms of CYP2D6 gene and gefitinib-induced hepatotoxicity. Clin. Lung Cancer. 2013;14:502–507. doi: 10.1016/j.cllc.2013.03.003. PubMed DOI

Kobayashi H., Sato K., Niioka T., Miura H., Ito H., Miura M. Relationship Among Gefitinib Exposure, Polymorphisms of Its Metabolizing Enzymes and Transporters, and Side Effects in Japanese Patients with Non-Small-Cell Lung Cancer. Clin. Lung Cancer. 2015;16:274–281. doi: 10.1016/j.cllc.2014.12.004. PubMed DOI

Kijima T., Shimizu T., Nonen S., Furukawa M., Otani Y., Minami T., Takahashi R., Hirata H., Nagatomo I., Takeda Y., et al. Safe and successful treatment with erlotinib after gefitinib-induced hepatotoxicity: Difference in metabolism as a possible mechanism. J. Clin. Oncol. 2011;29:e588–e590. doi: 10.1200/JCO.2010.34.3368. PubMed DOI

Hirose T., Fujita K., Kusumoto S., Oki Y., Murata Y., Sugiyama T., Ishida H., Shirai T., Nakashima M., Yamaoka T., et al. Association of pharmacokinetics and pharmacogenomics with safety and efficacy of gefitinib in patients with EGFR mutation positive advanced non-small cell lung cancer. Lung Cancer. 2016;93:69–76. doi: 10.1016/j.lungcan.2016.01.005. PubMed DOI

Swaisland H.C., Cantarini M.V., Fuhr R., Holt A. Exploring the relationship between expression of cytochrome P450 enzymes and gefitinib pharmacokinetics. Clin. Pharmacokinet. 2006;45:633–644. doi: 10.2165/00003088-200645060-00006. PubMed DOI

Khrunin A., Ivanova F., Moisseev A., Khokhrin D., Sleptsova Y., Gorbunova V., Limborska S. Pharmacogenomics of cisplatin-based chemotherapy in ovarian cancer patients of different ethnic origins. Pharmacogenomics. 2012;13:171–178. doi: 10.2217/pgs.11.140. PubMed DOI

Nakajima Y., Yoshitani T., Fukushima-Uesaka H., Saito Y., Kaniwa N., Kurose K., Ozawa S., Aoyagi N., Kamatani N., Yamamoto N., et al. Impact of the haplotype CYP3A4*16B harboring the Thr185Ser substitution on paclitaxel metabolism in Japanese patients with cancer. Clin. Pharmacol. Ther. 2006;80:179–191. doi: 10.1016/j.clpt.2006.04.012. PubMed DOI

The Cancer Genome Atlas (TCGA) [(accessed on 31 July 2020)]; Available online: https://www.cancer.gov/tcga/

Robey R.W., Pluchino K.M., Hall M.D., Fojo A.T., Bates S.E., Gottesman M.M. Revisiting the role of ABC transporters in multidrug-resistant cancer. Nat. Rev. Cancer. 2018;18:452–464. doi: 10.1038/s41568-018-0005-8. PubMed DOI PMC

Tate J.G., Bamford S., Jubb H.C., Sondka Z., Beare D.M., Bindal N., Boutselakis H., Cole C.G., Creatore C., Dawson E., et al. COSMIC: The Catalogue Of Somatic Mutations In Cancer. Nucleic Acids Res. 2019;47:D941–D947. doi: 10.1093/nar/gky1015. PubMed DOI PMC

Sondka Z., Bamford S., Cole C.G., Ward S.A., Dunham I., Forbes S.A. The COSMIC Cancer Gene Census: Describing genetic dysfunction across all human cancers. Nat. Rev. Cancer. 2018;18:696–705. doi: 10.1038/s41568-018-0060-1. PubMed DOI PMC

Jensen K.H., Izarzugaza J.M.G., Juncker A.S., Hansen R.B., Hansen T.F., Timshel P., Blondal T., Jensen T.S., Rygaard-Hjalsted E., Mouritzen P., et al. Analysis of a gene panel for targeted sequencing of colorectal cancer samples. Oncotarget. 2018;9:9043–9060. doi: 10.18632/oncotarget.24138. PubMed DOI PMC

McCawley N., Clancy C., O’Neill B.D., Deasy J., McNamara D.A., Burke J.P. Mucinous Rectal Adenocarcinoma Is Associated with a Poor Response to Neoadjuvant Chemoradiotherapy: A Systematic Review and Meta-analysis. Dis. Colon Rectum. 2016;59:1200–1208. doi: 10.1097/DCR.0000000000000635. PubMed DOI

Reynolds I.S., O’Connell E., Fichtner M., McNamara D.A., Kay E.W., Prehn J.H.M., Furney S.J., Burke J.P. Mucinous adenocarcinoma is a pharmacogenomically distinct subtype of colorectal cancer. Pharmacogenom. J. 2019;20:524–532. doi: 10.1038/s41397-019-0137-6. PubMed DOI

Li Y., Roberts N.D., Wala J.A., Shapira O., Schumacher S.E., Kumar K., Khurana E., Waszak S., Korbel J.O., Haber J.E., et al. Patterns of somatic structural variation in human cancer genomes. Nature. 2020;578:112–121. doi: 10.1038/s41586-019-1913-9. PubMed DOI PMC

Gerstung M., Jolly C., Leshchiner I., Dentro S.C., Gonzalez S., Rosebrock D., Mitchell T.J., Rubanova Y., Anur P., Yu K., et al. The evolutionary history of 2,658 cancers. Nature. 2020;578:122–128. doi: 10.1038/s41586-019-1907-7. PubMed DOI PMC

Smith J.C., Sheltzer J.M. Systematic identification of mutations and copy number alterations associated with cancer patient prognosis. eLife. 2018;7:e39217. doi: 10.7554/eLife.39217. PubMed DOI PMC

Santos M., Niemi M., Hiratsuka M., Kumondai M., Ingelman-Sundberg M., Lauschke V.M., Rodriguez-Antona C. Novel copy-number variations in pharmacogenes contribute to interindividual differences in drug pharmacokinetics. Genet. Med. 2018;20:622–629. doi: 10.1038/gim.2017.156. PubMed DOI

Ahmed J.H., Makonnen E., Fotoohi A., Aseffa A., Howe R., Aklillu E. CYP2D6 Genotype Predicts Plasma Concentrations of Tamoxifen Metabolites in Ethiopian Breast Cancer Patients. Cancers. 2019;11:1353. doi: 10.3390/cancers11091353. PubMed DOI PMC

Petrovic J., Pesic V., Lauschke V.M. Frequencies of clinically important CYP2C19 and CYP2D6 alleles are graded across Europe. Eur. J. Hum. Genet. 2020;28:88–94. doi: 10.1038/s41431-019-0480-8. PubMed DOI PMC

Cavallari L.H., Van Driest S.L., Prows C.A., Bishop J.R., Limdi N.A., Pratt V.M., Ramsey L.B., Smith D.M., Tuteja S., Duong B.Q., et al. Multi-site investigation of strategies for the clinical implementation of CYP2D6 genotyping to guide drug prescribing. Genet. Med. 2019;21:2255–2263. doi: 10.1038/s41436-019-0484-3. PubMed DOI PMC

Goetz M.P., Sun J.X., Suman V.J., Silva G.O., Perou C.M., Nakamura Y., Cox N.J., Stephens P.J., Miller V.A., Ross J.S., et al. Loss of heterozygosity at the CYP2D6 locus in breast cancer: Implications for germline pharmacogenetic studies. J. Natl. Cancer Inst. Monogr. 2014;107 doi: 10.1093/jnci/dju401. PubMed DOI PMC

Ng D., Hong C.S., Singh L.N., Johnston J.J., Mullikin J.C., Biesecker L.G. Assessing the capability of massively parallel sequencing for opportunistic pharmacogenetic screening. Genet. Med. 2017;19:357–361. doi: 10.1038/gim.2016.105. PubMed DOI PMC

Magnani L., Frige G., Gadaleta R.M., Corleone G., Fabris S., Kempe M.H., Verschure P.J., Barozzi I., Vircillo V., Hong S.P., et al. Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERalpha metastatic breast cancer. Nat. Genet. 2017;49:444–450. doi: 10.1038/ng.3773. PubMed DOI PMC

Lavrov A.V., Ustaeva O.A., Adilgereeva E.P., Smirnikhina S.A., Chelysheva E.Y., Shukhov O.A., Shatokhin Y.V., Mordanov S.V., Turkina A.G., Kutsev S.I. Copy number variation analysis in cytochromes and glutathione S-transferases may predict efficacy of tyrosine kinase inhibitors in chronic myeloid leukemia. PLoS ONE. 2017;12:e0182901. doi: 10.1371/journal.pone.0182901. PubMed DOI PMC

Genovese I., Ilari A., Assaraf Y.G., Fazi F., Colotti G. Not only P-glycoprotein: Amplification of the ABCB1-containing chromosome region 7q21 confers multidrug resistance upon cancer cells by coordinated overexpression of an assortment of resistance-related proteins. Drug Resist. Updat. 2017;32:23–46. doi: 10.1016/j.drup.2017.10.003. PubMed DOI

Hansen S.N., Ehlers N.S., Zhu S., Thomsen M.B., Nielsen R.L., Liu D., Wang G., Hou Y., Zhang X., Xu X., et al. The stepwise evolution of the exome during acquisition of docetaxel resistance in breast cancer cells. BMC Genom. 2016;17:442. doi: 10.1186/s12864-016-2749-4. PubMed DOI PMC

Spitzwieser M., Pirker C., Koblmuller B., Pfeiler G., Hacker S., Berger W., Heffeter P., Cichna-Markl M. Promoter methylation patterns of ABCB1, ABCC1 and ABCG2 in human cancer cell lines, multidrug-resistant cell models and tumor, tumor-adjacent and tumor-distant tissues from breast cancer patients. Oncotarget. 2016;7:73347–73369. doi: 10.18632/oncotarget.12332. PubMed DOI PMC

Sun Y., Shi N., Lu H., Zhang J., Ma Y., Qiao Y., Mao Y., Jia K., Han L., Liu F., et al. ABCC4 copy number variation is associated with susceptibility to esophageal squamous cell carcinoma. Carcinogenesis. 2014;35:1941–1950. doi: 10.1093/carcin/bgu043. PubMed DOI

Lek M., Karczewski K.J., Minikel E.V., Samocha K.E., Banks E., Fennell T., O’Donnell-Luria A.H., Ware J.S., Hill A.J., Cummings B.B., et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature. 2016;536:285–291. doi: 10.1038/nature19057. PubMed DOI PMC

Firth H.V., Richards S.M., Bevan A.P., Clayton S., Corpas M., Rajan D., Van Vooren S., Moreau Y., Pettett R.M., Carter N.P. DECIPHER: Database of Chromosomal Imbalance and Phenotype in Humans Using Ensembl Resources. Am. J. Hum. Genet. 2009;84:524–533. doi: 10.1016/j.ajhg.2009.03.010. PubMed DOI PMC

Clinvar. [(accessed on 31 July 2020)]; Available online: https://www.ncbi.nlm.nih.gov/clinvar/

Nath A., Lau E.Y.T., Lee A.M., Geeleher P., Cho W.C.S., Huang R.S. Discovering long noncoding RNA predictors of anticancer drug sensitivity beyond protein-coding genes. Proc. Natl. Acad. Sci. USA. 2019;116:22020–22029. doi: 10.1073/pnas.1909998116. PubMed DOI PMC

Wang Y., Fang Z., Hong M., Yang D., Xie W. Long-noncoding RNAs (lncRNAs) in drug metabolism and disposition, implications in cancer chemo-resistance. Acta. Pharm. Sin. B. 2020;10:105–112. doi: 10.1016/j.apsb.2019.09.011. PubMed DOI PMC

Zhang X., Yang H. Research Progress on Long Non-coding RNAs and Drug Resistance of Breast Cancer. Clin. Breast Cancer. 2020;20:275–282. doi: 10.1016/j.clbc.2019.11.001. PubMed DOI

Kansara S., Pandey V., Lobie P.E., Sethi G., Garg M., Pandey A.K. Mechanistic Involvement of Long Non-Coding RNAs in Oncotherapeutics Resistance in Triple-Negative Breast Cancer. Cells. 2020;9:1511. doi: 10.3390/cells9061511. PubMed DOI PMC

Fang Z., Chen W., Yuan Z., Liu X., Jiang H. LncRNA-MALAT1 contributes to the cisplatin-resistance of lung cancer by upregulating MRP1 and MDR1 via STAT3 activation. Biomed. Pharmacother. 2018;101:536–542. doi: 10.1016/j.biopha.2018.02.130. PubMed DOI

Meseure D., Vacher S., Lallemand F., Alsibai K.D., Hatem R., Chemlali W., Nicolas A., De Koning L., Pasmant E., Callens C., et al. Prognostic value of a newly identified MALAT1 alternatively spliced transcript in breast cancer. Br. J. Cancer Suppl. 2016;114:1395–1404. doi: 10.1038/bjc.2016.123. PubMed DOI PMC

Lee S.P., Hsieh P.L., Fang C.Y., Chu P.M., Liao Y.W., Yu C.H., Yu C.C., Tsai L.L. LINC00963 Promotes Cancer Stemness, Metastasis, and Drug Resistance in Head and Neck Carcinomas via ABCB5 Regulation. Cancers. 2020;12:1073. doi: 10.3390/cancers12051073. PubMed DOI PMC

Chen L., Bao Y., Piekos S.C., Zhu K., Zhang L., Zhong X.B. A Transcriptional Regulatory Network Containing Nuclear Receptors and Long Noncoding RNAs Controls Basal and Drug-Induced Expression of Cytochrome P450s in HepaRG Cells. Mol. Pharmacol. 2018;94:749–759. doi: 10.1124/mol.118.112235. PubMed DOI PMC

Chen L., Bao Y., Jiang S., Zhong X.B. The Roles of Long Noncoding RNAs HNF1alpha-AS1 and HNF4alpha-AS1 in Drug Metabolism and Human Diseases. Non-Coding RNA. 2020;6:24. doi: 10.3390/ncrna6020024. PubMed DOI PMC

Hu Y., Zhu Q.N., Deng J.L., Li Z.X., Wang G., Zhu Y.S. Emerging role of long non-coding RNAs in cisplatin resistance. Onco. Targets Ther. 2018;11:3185–3194. doi: 10.2147/OTT.S158104. PubMed DOI PMC

Nekvindova J., Mrkvicova A., Zubanova V., Hyrslova Vaculova A., Anzenbacher P., Soucek P., Radova L., Slaby O., Kiss I., Vondracek J., et al. Hepatocellular carcinoma: Gene expression profiling and regulation of xenobiotic-metabolizing cytochromes P450. Biochem. Pharmacol. 2020;177:113912. doi: 10.1016/j.bcp.2020.113912. PubMed DOI

Role of Genetic Variation in Cytochromes P450 in Breast Cancer Prognosis and Therapy Response